Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4052145 | 0.87 | PARP1 (0.76) | PARP1CYP1A2 | |
| SCHEMBL4056163 | 0.87 | PARP1 (0.69) | PARP1CYP1A2 | |
| SCHEMBL4053090 | 0.87 | PARP1 (0.88) | PARP1CYP1A2 | |
| SCHEMBL4051261 | 0.84 | PARP1 (0.71) | PARP1CYP1A2 | |
| SCHEMBL4052768 | 0.83 | PARP1 (0.69) | PARP1CYP1A2 | |
| SCHEMBL4046748 | 0.83 | PARP1 (0.69) | PARP1CYP1A2 | |
| SCHEMBL4053728 | 0.82 | PARP1 (0.80) | PARP1CYP1A2 | |
| SCHEMBL4054595 | 0.81 | PARP1 (0.70) | PARP1CYP1A2 | |
| SCHEMBL4054673 | 0.81 | PARP1 (0.67) | PARP1CYP1A2 | |
| SCHEMBL4048087 | 0.81 | PARP1 (0.69) | PARP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069351-B1 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBVIE INC (US) | 2015-10-28 | — | — | EP | claimed |
| US-8183250-B2 | Potent PARP inhibitors | ABBOTT LABORATORIES (US) | 2012-05-22 | — | — | US | claimed |
| US-20090298858-A1 | POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-12-03 | — | — | US | claimed |
| US-20080015182-A1 | Potent PARP Inhibitors | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | claimed |
| EP-2069351-B1 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBVIE INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8183250-B2 | Potent PARP inhibitors | ABBOTT LABORATORIES (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090298858-A1 | POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2069351-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080015182-A1 | Potent PARP Inhibitors | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | disclosed |
| WO-2007149907-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298858-A1 | POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885CYP1A2 782/4885 |
| US-20080015182-A1 | Potent PARP Inhibitors | PARP1, PARP2, PARP3 | PARP1 1/4885CYP1A2 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.